☆ 4.7 Letter

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

DIABETES OBESITY & METABOLISM (2023)

Get Full Text
Add to Collection

Journal

DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1111/dom.15340

Keywords

canagliflozin; cardiovascular; clinical trials; heart failure; timing of benefits

Categories

Endocrinology & Metabolism

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.